Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
Merck acquired OncoImmune and its COVID-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.
The U.S. Food and Drug Administration (FDA) has a busy end of November planned, with numerous PDUFA dates to address. Here’s a look at the upcoming week.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
Here’s a look at recent clinical trial pauses around the biopharma industry.
Merck and Eisai announced today that they have new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors.
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
JOBS
IN THE PRESS